Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Bend Opens Spray-Drying Facility

By Drug Discovery Trends Editor | August 30, 2012

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announces the addition of a current Good Manufacturing Practice (cGMP) spray-drying facility.  The facility expands Bend Research’s capabilities and expertise in the area of development and manufacture of high-potency drug candidates.

The facility is well-suited for the manufacture of a wide range of compound types and safety classifications, ranging from inhalable biotherapeutics to oral solid form high-potency small molecules.  The facility is physically separated from the company’s other development and cGMP manufacturing facilities and is designed for high containment operations at the highest safety and quality standards, utilizing the latest best-practice design features, finishes and engineering controls at the equipment level.

“We’re excited to offer our clients expanded cGMP spray-drying capability for high-potency compounds,” said Rod Ray, chief executive officer.  “This facility will complement our small-molecule cGMP spray drying capabilities.”

In addition to the high-potency spray-drying facility, the company recently expanded its solid-dosage-form capability and purchased an additional building for future expansion of development and manufacturing capabilities.

Date: August 24, 2012
Source: Bend Research Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE